Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €3.75 EUR
Change Today -0.032 / -0.85%
Volume 460.9K
EVT On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
Frankfurt
As of 2:16 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

evotec ag (EVT) Snapshot

Open
€3.75
Previous Close
€3.78
Day High
€3.80
Day Low
€3.71
52 Week High
05/21/15 - €4.14
52 Week Low
10/16/14 - €2.42
Market Cap
493.6M
Average Volume 10 Days
746.4K
EPS TTM
€0.08
Shares Outstanding
131.8M
EX-Date
--
P/E TM
48.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOTEC AG (EVT)

Related News

No related news articles were found.

evotec ag (EVT) Related Businessweek News

No Related Businessweek News Found

evotec ag (EVT) Details

Evotec AG provides drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as anti-infectives, target identification and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism, and excretion) profiling, proteomics, cell and protein production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage, including EVT302 that has completed Phase II clinical trials for the treatment of Alzheimer's disease; EVT201, which is in Phase II clinical trials for the treatment of insomnia; Somatoprim that is in Phase II clinical trials for the treatment of Acromegaly; EVT100, which has completed Phase I clinical trials for the treatment of CNS diseases; EVT401 that has completed Phase I clinical trials for the treatment of inflammation; and ND, a Phase I clinical trial product for the treatment of oncology. Its pre-clinical stage products include ND for pain and oncology, and EVT770 for diabetes type 2/1; and discovery stage products comprise various products for inflammation, diabetes type 2/1, kidney disease, oncology, Alzheimer’s disease, and CNS/MS. The company has alliances and partnerships with AstraZeneca AB, Bayer Pharma AG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., Jain Foundation Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Novartis AG, F. Hoffmann-La Roche AG, Shire plc, and UCB Pharma. It also has strategic collaborations with Apeiron Biologics AG, Fraunhofer Institute for Molecular Biology and Applied Ecology, and Sanofi; and collaboration with Convergence Pharmaceuticals Holdings Ltd., Debiopharm Group, Eternygen GmbH, Medicines for Malaria Venture, and Second Genome, Inc. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

956 Employees
Last Reported Date: 08/12/15
Founded in 1993

evotec ag (EVT) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €459.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €323.0K
Chief Operating Officer and Member of Managem...
Total Annual Compensation: €361.0K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €361.0K
Compensation as of Fiscal Year 2014.

evotec ag (EVT) Key Developments

Evotec and CHDI Foundation Expand Ongoing Collaboration to Fight Huntington’s Disease Using Evotec’s Expanded Capabilities and Footprint

Evotec AG announced that CHDI Foundation Inc. has extended and expanded its collaboration with Evotec through to August 2018. Over this period CHDI will fund 55 full-time scientists at Evotec. The collaboration which aims to find new treatments for Huntington's disease, an inherited neurodegenerative disorder will take advantage of additional technologies, capabilities and capacities at Evotec's facilities in Toulouse, France, and Princeton, NJ, USA. The extension of this collaboration is a further validation of Evotec's investment in new technologies and capabilities in support of driving innovative drug discovery collaborations. Evotec provides CHDI with a full range of research activities and expertise in the neuroscience area, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics and protein production.

Evotec AG Reports Consolidated Earnings Results for the Second Quarter and First Half ended June 30, 2015; Records Impairment of Intangible Assets; Reaffirms Earnings Guidance for Fiscal 2015

Evotec AG reported consolidated earnings results for the second quarter and first half ended June 30, 2015. The company reported revenue of EUR 33,416,000, operating result of EUR 16,222,000, adjusted EBITDA of EUR 1,222,000, net result of EUR 14,627,000 or EUR 0.11 per basic and diluted share against revenue of EUR 22,474,000, operating loss of EUR 83,000, adjusted EBITDA of EUR 1,914,000, net loss of EUR 422,000 or EUR 0.00 per basic and diluted share a year ago. For the first half, the company reported revenue of EUR 54,958,000, operating result of EUR 12,922,000, adjusted EBITDA of EUR 795,000, net result of EUR 13,555,000 or EUR 0.10 per basic and diluted share against revenue of EUR 40,085,000, operating loss of EUR 3,565,000, adjusted EBITDA of EUR 607,000, net loss of EUR 4,428,000 or EUR 0.03 per basic and diluted share a year ago. The increase in revenue is due to growth in the core EVT Execute business, the contribution of the Sanofi collaboration, milestone achievements and favourable foreign exchange rate effects. Excluding milestones, upfronts and licences and revenue contributions from the acquired businesses of Bionamics, Euprotec and Sanofi, Evotec's revenues for the first half of 2015 were EUR 41.1 million and increased by 3% over the same period of the previous year against EUR 39.9 million a year ago. The company recorded impairment of intangible assets of EUR 69,000. In 2015, total group revenues excluding milestones, upfronts and licences are expected to increase more than 35%. EBITDA before changes in contingent considerations is expected to be positive.

Evotec, Apeiron Biologics and Sanofi Jointly Develop Novel Small Molecule-Based Cancer Immunotherapies

Evotec AG and Apeiron Biologics AG announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. This collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematopoietic cancers by enhancing the anti-tumour activity of human lymphocytes. Based on Evotec’s technological expertise and Apeiron Biologics’ immunological know-how, the collaboration will also focus on the identification of novel small molecule hits and their targets for next-generation therapies in immuno-oncology which are expected to complement the current offerings of checkpoint inhibitors. The collaboration is set up as an initiative to support long-term pipeline building for Evotec, Apeiron Biologics and Sanofi. All three companies will make significant contributions to this collaboration in terms of scientific expertise, technological platforms and resources. The collaboration will further enhance and complement Sanofi’s extensive oncology portfolio. It will enable Evotec to enter into the drug discovery area of immuno-oncology and it will substantially support Apeiron Biologics’ strategy focusing on novel and innovative checkpoint inhibiting approaches. The agreement triggers two years of substantial research payments for Evotec and Apeiron Biologics with the opportunity to receive pre-clinical, clinical, regulatory and commercial milestones which could total over €200 million as well as royalties upon commercialisation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVT:GR €3.75 EUR -0.032

EVT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $5.62 USD -0.15
CTI BioPharma Corp $1.52 USD -0.03
Cytokinetics Inc $7.20 USD +0.16
GlaxoSmithKline SAE £10.00 EGP +0.01
Infinity Pharmaceuticals Inc $8.65 USD +0.09
View Industry Companies
 

Industry Analysis

EVT

Industry Average

Valuation EVT Industry Range
Price/Earnings 45.1x
Price/Sales 4.8x
Price/Book 2.8x
Price/Cash Flow 36.7x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG, please visit www.evotec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.